Patient Derived Organoid Models

Organoid, globular and 3D cell models have great potentials in many applications, including disease modeling and regenerative medicine. Patient derived organoid (PDO), described as a miniature three-dimensional (3D) cell culture derived from a patient's cancer cells, has been subjected to extensive investment and experimental validation to provide potential therapeutic options for the detection of complex diseases. Creative Biolabs is dedicated to providing a variety of disease-related organ research to improve the accuracy and effectiveness of future cancer treatment and drug response.

Fig 1 Exploiting adult stem cell-derived organoids for immunotherapy.

Our PDO Model Portfolio

We are able to select a large number of patients as the research objects, stratify the risk according to the types and stages of tumors, and store the research results in PDOs in biobank for future experiments.

• We can easily capture the genetic diversity of the disease through medical assistance and clinical practice.
• A well-scaled laboratory can grow a large number of patient derived organoid-like cells or tissues.
• Organoids from patient samples can be used as a model of individual cancer to guide clinical decisions.

In future clinical trials, screening of organoids can be evaluated. High-throughput screening of organoids, combined with next-generation sequencing, proteomic analysis and other advanced molecular diagnostic methods, can make cancer treatment more effective with fewer side effects.

Our PDO Collections

Biomedical researchers are using artificial cultures to grow large numbers of organ-like cells or tissues. These include some common clinical disease treatment directions, such as colorectal cancer, pancreatic cancer, lung cancer, bladder breast, oesophageal carcinoma and so on. As described in detail in patient derived xenografted models (PDX model), our PDO model will provide a rapid and low-cost potential tool for preclinical drug screening and prediction of individualized cancer treatment responses. Creative Biolabs is committed to providing individualized treatment for individual patients who have exhausted standard clinical protocols.

Creative Biolabs focuses on commercializing its analysis services using PDO model-based and technology-based approaches. We provide products and services in the field of in vitro drug metabolism and pharmacokinetics (DMPK), in vitro absorption, distribution, metabolism, excretion (ADME) and digital pathology using cell model and analytical techniques. For detailed information, please feel free to contact us.

Reference

1. Drost J, Clevers H. Translational applications of adult stem cell-derived organoids[J]. Development, 2017, 144(6): 968-975.